We assessed the predictive value of new radiomic features characterizing the lesion dissemination in baseline 18F-FDG PET and tested whether combining them with baseline metabolic tumour volume (MTV) could improve prediction of progression free survival (PFS) and overall survival (OS) in diffuse large B cell lymphoma (DLBCL) patients.